Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RSV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vaxxas Licenses RSV Vaccine from NIH for Advanced Development
Details : NIH has granted the company a license to a next-generation vaccine antigen (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV).
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : RSV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : H7N9-targeted Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vaxxas Initiates Phase I Trial For Avian Influenza Vaccine Using HD-MAP Technology
Details : Vaxxas’ high-density microarray patch (HD-MAP) technology uses an array of microprojections to deliver the vaccine, against pre-pandemic avian influenza strain H7N9, to the skin.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 11, 2024
Lead Product(s) : H7N9-targeted Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Typhoid Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : SK Bioscience
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 24, 2023
Lead Product(s) : Typhoid Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : SK Bioscience
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Typhoid Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Wellcome
Deal Size : $3.6 million
Deal Type : Funding
Details : The funding will support the IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 23, 2023
Lead Product(s) : Typhoid Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Wellcome
Deal Size : $3.6 million
Deal Type : Funding
Lead Product(s) : HexaPro
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HexaPro, a second-generation version of the spike protein used in all major U.S. approved COVID-19 vaccines, which was modified to be more stable and immunogenic than its predecessor, giving potential coverage of all known SARS-CoV-2 variants.
Brand Name : HexaPro
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 05, 2023
Lead Product(s) : HexaPro
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inactivated Seasonal Influenza Vaccine Quadrivalent
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The vaccine being delivered by the Vaxxas HD-MAP in this Phase I clinical trial is a commercially available seasonal flu vaccine (IIV4) targeting four significant strains of the influenza virus.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 09, 2023
Lead Product(s) : Inactivated Seasonal Influenza Vaccine Quadrivalent
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HexaPro
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : OneVentures
Deal Size : $23.0 million
Deal Type : Financing
Details : The financing will accelerate the clinical program for Vaxxas’ COVID-19 vaccine patch candidate which is based upon the company’s proprietary HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved C...
Brand Name : HexaPro
Molecule Type : Vaccine
Upfront Cash : Undisclosed
December 05, 2022
Lead Product(s) : HexaPro
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : OneVentures
Deal Size : $23.0 million
Deal Type : Financing
Lead Product(s) : HexaPro
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HexaPro, a highly stabilized protein that is designed to mimic the structure of the spike protein on the surface of the coronavirus to train the human immune system to recognize and fight SARS-CoV-2 infection.
Brand Name : HexaPro
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 08, 2022
Lead Product(s) : HexaPro
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Recombinant SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The license obtained by Vaxxas from the United States’ National Institutes of Health, enables Vaxxas to create the first needle-free, room-temperature stable, SARS-CoV-2 spike subunit vaccine (HexaPro) patch to enter clinical studies.
Brand Name : HexaPro
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Recombinant SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : HD-MAP
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal model.
Brand Name : HD-MAP
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 02, 2021
Lead Product(s) : HD-MAP
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?